Samjin Pharmaceutical Co., Ltd.(KR:005500)
â‚©20,150.00+390.00 (+1.97%)
KR:005500
Samjin Pharmaceutical Co., Ltd. financials statements
â‚©20,150.00
At close:+390.00 (+1.97%)
Want to see KR:005500 full AI Analyst Report?
Samjin Pharmaceutical Co., Ltd. (005500) Ratios
Samjin Pharmaceutical Co., Ltd. Ratios
KR:005500's free cash flow for Q2 2026 was ₩13.31B. For the 2026 fiscal year, KR:005500's free cash flow was decreased by ₩-1.28B and operating cash flow was ₩14.58B. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.30 | 1.00 | 1.01 | 1.64 | 2.82 |
| Quick Ratio | 0.55 | 0.42 | 0.46 | 0.80 | 1.42 |
| Cash Ratio | 0.08 | 0.02 | 0.02 | 0.03 | 0.16 |
| Solvency Ratio | 0.24 | 0.35 | 0.23 | 0.24 | 0.36 |
| Operating Cash Flow Ratio | 0.15 | 0.24 | 0.06 | 0.21 | 0.48 |
| Short-Term Operating Cash Flow Coverage | 0.21 | 0.32 | 0.07 | 0.39 | 1.69 |
| Net Current Asset Value | â‚© 11.44B | â‚© -4.41B | â‚© -8.36B | â‚© 3.58B | â‚© 41.54B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.29 | 0.29 | 0.28 | 0.22 | 0.16 |
| Debt-to-Equity Ratio | 0.47 | 0.46 | 0.45 | 0.32 | 0.23 |
| Debt-to-Capital Ratio | 0.32 | 0.32 | 0.31 | 0.24 | 0.19 |
| Long-Term Debt-to-Capital Ratio | 0.09 | 0.00 | 0.02 | 0.13 | 0.15 |
| Financial Leverage Ratio | 1.62 | 1.62 | 1.58 | 1.48 | 1.42 |
| Debt Service Coverage Ratio | 0.42 | 0.49 | 0.34 | 0.73 | 2.51 |
| Interest Coverage Ratio | 4.99 | 6.49 | 4.41 | 13.15 | 238.94 |
| Debt to Market Cap | 0.56 | 0.53 | 0.42 | 0.27 | 0.17 |
| Interest Debt Per Share | 11495.55 | 10014.28 | 9502.26 | 7045.66 | 4441.79 |
| Net Debt to EBITDA | 2.78 | 1.79 | 3.18 | 2.31 | 1.10 |
| Profitability Margins | |||||
| Gross Profit Margin | 49.50% | 41.82% | 49.94% | 42.96% | 47.12% |
| EBIT Margin | 7.98% | 15.74% | 6.84% | 9.85% | 14.02% |
| EBITDA Margin | 14.40% | 21.38% | 12.53% | 13.43% | 16.96% |
| Operating Profit Margin | 7.98% | 10.26% | 6.67% | 8.46% | 13.56% |
| Pretax Profit Margin | 7.15% | 14.15% | 5.34% | 9.21% | 13.96% |
| Net Profit Margin | 7.82% | 12.72% | 6.47% | 7.99% | 11.36% |
| Continuous Operations Profit Margin | 7.82% | 12.72% | 6.49% | 7.99% | 11.36% |
| Net Income Per EBT | 109.37% | 89.90% | 121.23% | 86.79% | 81.36% |
| EBT Per EBIT | 89.53% | 137.94% | 79.99% | 108.81% | 102.95% |
| Return on Assets (ROA) | 5.14% | 9.23% | 4.50% | 5.39% | 8.54% |
| Return on Equity (ROE) | 8.32% | 14.99% | 7.13% | 7.95% | 12.13% |
| Return on Capital Employed (ROCE) | 7.63% | 11.89% | 7.08% | 7.14% | 11.98% |
| Return on Invested Capital (ROIC) | 5.73% | 7.35% | 5.00% | 5.44% | 9.27% |
| Return on Tangible Assets | 5.38% | 9.72% | 4.73% | 5.53% | 8.82% |
| Earnings Yield | 9.99% | 17.22% | 6.74% | 6.74% | 8.78% |
| Efficiency Ratios | |||||
| Receivables Turnover | 4.66 | 4.92 | 4.75 | 4.58 | 4.34 |
| Payables Turnover | 10.13 | 11.02 | 13.13 | 11.86 | 10.81 |
| Inventory Turnover | 1.41 | 1.96 | 1.84 | 2.28 | 1.90 |
| Fixed Asset Turnover | 1.65 | 1.60 | 1.52 | 1.38 | 1.48 |
| Asset Turnover | 0.66 | 0.73 | 0.70 | 0.67 | 0.75 |
| Working Capital Turnover Ratio | 13.93 | 384.22 | 10.77 | 3.83 | 2.46 |
| Cash Conversion Cycle | 301.45 | 227.72 | 247.67 | 209.17 | 242.83 |
| Days of Sales Outstanding | 78.35 | 74.19 | 76.78 | 79.76 | 84.20 |
| Days of Inventory Outstanding | 259.13 | 186.66 | 198.68 | 160.19 | 192.41 |
| Days of Payables Outstanding | 36.03 | 33.13 | 27.80 | 30.78 | 33.77 |
| Operating Cycle | 337.48 | 260.85 | 275.47 | 239.95 | 276.60 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 1814.66 | 3025.12 | 643.47 | 1364.79 | 1948.09 |
| Free Cash Flow Per Share | 812.91 | 1571.12 | -956.50 | -1436.72 | -4115.69 |
| Dividend Paid and CapEx Coverage Ratio | 1.01 | 1.34 | 0.27 | 0.38 | 0.28 |
| Capital Expenditure Coverage Ratio | 1.81 | 2.08 | 0.40 | 0.49 | 0.32 |
| Operating Cash Flow Coverage Ratio | 0.16 | 0.31 | 0.07 | 0.20 | 0.44 |
| Operating Cash Flow to Sales Ratio | 0.07 | 0.12 | 0.03 | 0.06 | 0.10 |
| Free Cash Flow Yield | 4.12% | 8.69% | -4.42% | -5.60% | -15.65% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 10.06 | 5.81 | 14.83 | 14.84 | 11.39 |
| Price-to-Sales (P/S) Ratio | 0.78 | 0.74 | 0.96 | 1.19 | 1.29 |
| Price-to-Book (P/B) Ratio | 0.83 | 0.87 | 1.06 | 1.18 | 1.38 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 24.30 | 11.50 | -22.63 | -17.85 | -6.39 |
| Price-to-Operating Cash Flow Ratio | 10.88 | 5.97 | 33.65 | 18.79 | 13.50 |
| Price-to-Earnings Growth (PEG) Ratio | -0.27 | 0.05 | -0.96 | -0.59 | 6.05 |
| Enterprise Value Multiple | 8.22 | 5.25 | 10.84 | 11.14 | 8.73 |
| Enterprise Value | 365.79B | 345.90B | 396.63B | 410.18B | 370.13B |
| EV to EBITDA | 8.22 | 5.25 | 10.84 | 11.14 | 8.73 |
| EV to Sales | 1.18 | 1.12 | 1.36 | 1.50 | 1.48 |
| EV to Free Cash Flow | 36.73 | 17.46 | -32.02 | -22.53 | -7.31 |
| EV to Operating Cash Flow | 16.45 | 9.07 | 47.59 | 23.72 | 15.44 |
| Tangible Book Value Per Share | 21942.00 | 19039.88 | 18922.44 | 20955.29 | 18195.19 |
| Shareholders’ Equity Per Share | 23701.82 | 20746.52 | 20489.92 | 21730.25 | 19033.41 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.09 | 0.10 | -0.21 | 0.13 | 0.19 |
| Revenue Per Share | 25231.27 | 24448.93 | 22556.45 | 21626.69 | 20325.97 |
| Net Income Per Share | 1972.73 | 3110.77 | 1460.00 | 1727.87 | 2308.72 |
| Tax Burden | 1.09 | 0.90 | 1.21 | 0.87 | 0.81 |
| Interest Burden | 0.90 | 0.90 | 0.78 | 0.93 | 1.00 |
| Research & Development to Revenue | 0.12 | 0.01 | 0.01 | 0.01 | 0.01 |
| SG&A to Revenue | 0.14 | 0.13 | 0.14 | 0.16 | 0.14 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.92 | 0.97 | 0.44 | 0.79 | 0.84 |
Currency in KRW

